{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:09:09Z","timestamp":1794276549466,"version":"4.9.0"},"reference-count":26,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the perioperative morbidity and mortality associated with direct oral anticoagulants (DOACs) and warfarin for patients receiving transurethral resection of prostate (TURP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      This was a single\u2010centre, retrospective cohort analysis of patients who underwent TURP for benign prostate hyperplasia from April 2019 to December 2023. The primary objective was to evaluate the perioperative bleeding and thromboembolic risk between anticoagulated (AC) vs no\u2010AC patients. The secondary objective was to evaluate perioperative bleeding and thromboembolic risk between different formulations of DOACs. Patient demographics, prior treatment, prostate size, baseline bleeding risk, and operative details were collected. Bleeding and thromboembolic\u2010related morbidity were captured within a 3\u2010month postoperative period. Perioperative management of AC therapy was recorded, and all patients had their AC therapy withheld. Cohort characteristic between the AC vs no\u2010AC, and DOAC groups were analysed with two\u2010sided\n                      <jats:italic>t<\/jats:italic>\n                      \u2010test, and chi\u2010square test. Further logistic regression analyses were carried out to identified significant variables between the groups. These significant variables were used for adjustment in inverse probability\u2010weighted treatment effect analysis to evaluate bleeding risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 629 patients in the cohort, and 113 (18%) patients were receiving AC therapy. The AC patients were at 1.6 times statistically significant increased risk of acute bleeding, and 11 times increased risk of prolonged haematuria for &gt;14\u2009days. When compared to apixaban, patients on rivaroxaban conferred a statistically significant increased risk of acute bleeding by 2.21 times. Patients receiving AC therapy had a statistically significant increased risk of stroke in the perioperative setting (no\u2010AC vs AC: 0.4% vs 2.7%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study to evaluate risk of bleeding for TURP patients receiving DOACs. The AC patients are more likely to experience haematuria and stroke in the perioperative period despite withholding therapy. Apixaban appears to cause less bleeding\u2010related complications than rivaroxaban.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16478","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:43:46Z","timestamp":1724982226000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of perioperative bleeding risk between direct oral anticoagulants in transurethral resection of prostate"],"prefix":"10.1111","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9193-2449","authenticated-orcid":false,"given":"Lu Yu","family":"Kuo","sequence":"first","affiliation":[{"name":"Department of Urology Gold Coast University Hospital  Southport Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-494X","authenticated-orcid":false,"given":"Jenny","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology Gold Coast University Hospital  Southport Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-4997","authenticated-orcid":false,"given":"Joshua","family":"Silverman","sequence":"additional","affiliation":[{"name":"Department of Urology Gold Coast University Hospital  Southport Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Jae Yeun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology Gold Coast University Hospital  Southport Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Letch","sequence":"additional","affiliation":[{"name":"School of Medicine and Dentistry Griffith University  Southport Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"McClintock","sequence":"additional","affiliation":[{"name":"Department of Urology Gold Coast University Hospital  Southport Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03607-7"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000499"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-020-00985-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)40731-2"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2011.106"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1308\/003588409X391820"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1308\/003588406X95084"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.04.103"},{"issue":"1","key":"e_1_2_8_10_1","first-page":"1","article-title":"Benign prostatic hyperplasia: epidemiology, economics and evaluation","volume":"22","author":"Vuichoud C","year":"2015","journal-title":"Can J Urol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026723"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316340"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2023.02.025"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1989.tb05322.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00609.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0561-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10686.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287218807591"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2015.0115"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2158"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21222"},{"key":"e_1_2_8_22_1","first-page":"179","article-title":"A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban","volume":"6","author":"Frost C","year":"2014","journal-title":"Clin Pharmacol"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.04.002"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00824.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2021.05.011"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:47:07Z","timestamp":1761724027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":26,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/bju.16478"],"URL":"https:\/\/doi.org\/10.1111\/bju.16478","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"2024-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}